Clinical Trials

52 enrolled

CNS

Glioblastoma

NCT05882734 2026-02-17

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

61 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT03233139 2026-02-12

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

146 enrolled

Advanced Malignancies

NCT06190951 2026-02-10

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Phase 1 Active not recruiting

151 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT02651662 2026-02-02

CLIO-1

105 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT05785767 2026-01-22

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2/3 Active not recruiting

850 enrolled

Phase 2/3 Active not recruiting

Advanced Non-Small Cell Lung Cancer

NCT05800015 2026-01-22

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

950 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06161441 2026-01-12

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

195 enrolled

Phase 3 Active not recruiting

Resectable Non-small Cell Lung Cancer

NCT03969004 2025-09-19

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

415 enrolled 1 FDA

Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT06269133 2025-08-27

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Active not recruiting

1,000 enrolled

Advanced Non-small Cell Lung Cancer

NCT04305795 2025-06-19

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Phase 3 Active not recruiting

23 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05608291 2025-05-13

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

1,564 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT03916627 2025-04-11

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

GastrointestinalHead & NeckThoracic

65 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT05662397 2025-02-04

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

77 enrolled

Neoplasms, Recurrence

NCT04050436 2025-01-27

CERPASS

231 enrolled

Tumor-Agnostic

Carcinoma, Carcinoma, Squamous Cell

NCT05669989 2025-01-23

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Plasma cell

Multiple Myeloma

NCT03294083 2022-10-27

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma